151
|
Cho JH, Choi WS, Huh KR, Won JE, Lee YK, Zang DY, Kim HJ. A Case of Immunoglobulin Therapy for Pure Red Cell Aplasia Induced by Parvovirus B19. Korean J Hematol 2007. [DOI: 10.5045/kjh.2007.42.3.283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Jae Hyun Cho
- Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Korea
| | - Won Sub Choi
- Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Korea
| | - Kyung Rim Huh
- Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Korea
| | - Ji Eon Won
- Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Korea
| | - Young Kyung Lee
- Department of Laboratory Medicine, College of Medicine, Hallym University, Chuncheon, Korea
| | - Dae Young Zang
- Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Korea
| | - Hyo Jung Kim
- Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Korea
| |
Collapse
|
152
|
Zang DY. A New Option for Advanced Gastric Cancer -Docetaxel and Novel Oral Fluoropyrimidine Combination Chemotherapy-. J Korean Med Assoc 2007. [DOI: 10.5124/jkma.2007.50.6.556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Affiliation(s)
- Dae Young Zang
- Department of Internal Medicine, Hallym University College of Medicine, Korea.
| |
Collapse
|
153
|
Kim JH, Lee DH, Shin HC, Kwon JH, Jung JY, Kim HJ, Song HH, Lee KS, Zang DY, Ahn JS, Park YL, Lee JA. A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2006; 54:57-62. [PMID: 16884818 DOI: 10.1016/j.lungcan.2006.06.013] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2006] [Revised: 06/23/2006] [Accepted: 06/25/2006] [Indexed: 11/29/2022]
Abstract
BACKGROUND The combination of gemcitabine and cisplatin is among the most active regimens for the treatment of NSCLC. However, the optimal dose and schedule for administration of the two drugs has not yet been determined. We investigated the activity and toxicity of a gemcitabine and split-dose cisplatin regimen in an outpatient setting for patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS From June 2004 to May 2005 patients with stage IIIB or IV who had not had prior chemotherapy entered the study. Treatment consisted of gemcitabine 1250 mg/m2 and cisplatin 35 mg/m2, both given intravenously on days 1 and 8 every 21 days. RESULTS Forty-five patients were entered this study. Patient characteristics were as follows: male/female, 34/11; median age (range), 62 (30-76) years; ECOG PS 0/1/2, 7/30/8; stage IIIB/IV, 18/27. A total of 168 cycles were delivered, with a median of 4 cycles (range, 1-6). All patients were evaluable for toxicity. Grade 3 and 4 toxicities according to the NCI toxicity criteria included neutropenia in 8 patients (18%), anemia in 4 (9%), thrombocytopenia in 7 (15%), and emesis in 1 (2%). Of 42 patients assessable for response, 23 patients showed a partial remission. On intent-to-treat basis, the overall response rate was 51% (95% CI, 37-65%). Median time to progression was 6.0 months (range, 1.2-12.0 months) and median overall survival was 13.1 months (range, 1.4-17 months). CONCLUSIONS This regimen with gemcitabine and split-dose cisplatin using a 21-day schedule appears to be active and very well-tolerated in an outpatients setting for patients with advanced NSCLC.
Collapse
Affiliation(s)
- Jung Han Kim
- Department of Internal Medicine, Hallym University College of Medicine, Seoul, Republic of Korea.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
154
|
Lee JH, Choi SJ, Lee JH, Park JH, Kim H, Joo YD, Lee WS, Zang DY, Kim HJ, Lee KH. Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia. Ann Hematol 2006; 85:357-65. [PMID: 16575580 DOI: 10.1007/s00277-006-0110-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2006] [Accepted: 03/13/2006] [Indexed: 10/24/2022]
Abstract
The benefits of intensive post-remission chemotherapy have not been verified in elderly patients with acute myeloid leukemia (AML). To reduce fatal complications caused by intensive post-remission therapy, we performed a prospective phase II multicenter trial of standard induction chemotherapy ('7+3' of cytarabine plus daunorubicin), followed by two cycles of attenuated consolidation therapy ('5+1' of cytarabine plus daunorubicin) for elderly patients with AML, excluding those with M3. Of the 41 patients enrolled in the study, 24 (58.5%) attained CR. Of these 24, 17 (70.8%) completed both planned cycles of consolidation therapy. After a median follow-up of 566 days (range, 63-1190 days) among surviving patients, 15 relapsed, with an actuarial 3-year disease-free survival rate of 22.5%. There were no fatal complications during consolidation therapy. Actuarial 3-year overall survival was 17.0%. These findings suggest that, when compared with previous findings using more intensive consolidation therapy, attenuated consolidation therapy does not compromise outcomes in elderly AML patients.
Collapse
MESH Headings
- Acute Disease
- Aged
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Disease-Free Survival
- Female
- Flow Cytometry
- Humans
- Immunophenotyping/methods
- Leukemia, Erythroblastic, Acute/drug therapy
- Leukemia, Erythroblastic, Acute/immunology
- Leukemia, Erythroblastic, Acute/pathology
- Leukemia, Megakaryoblastic, Acute/drug therapy
- Leukemia, Megakaryoblastic, Acute/immunology
- Leukemia, Megakaryoblastic, Acute/pathology
- Leukemia, Monocytic, Acute/drug therapy
- Leukemia, Monocytic, Acute/immunology
- Leukemia, Monocytic, Acute/pathology
- Leukemia, Myeloid/drug therapy
- Leukemia, Myeloid/immunology
- Leukemia, Myeloid/pathology
- Leukemia, Myeloid, Acute/drug therapy
- Leukemia, Myeloid, Acute/immunology
- Leukemia, Myeloid, Acute/pathology
- Leukemia, Myelomonocytic, Acute/drug therapy
- Leukemia, Myelomonocytic, Acute/immunology
- Leukemia, Myelomonocytic, Acute/pathology
- Male
- Middle Aged
- Prognosis
- Prospective Studies
- Treatment Outcome
Collapse
Affiliation(s)
- Je-Hwan Lee
- Department of Internal Medicine, Asan Medical Center, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, South Korea.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
155
|
Kim TW, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS, Zang DY, Lee KH, Kang YK, Kim SR, Kim HK. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial. Acta Oncol 2005; 44:230-5. [PMID: 16076694 DOI: 10.1080/02841860510029590] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
A phase II study was conducted to assess the efficacy and tolerability of capecitabine in combination with irinotecan (CAPIRI) in advanced colorectal cancer. Forty-seven patients with previously untreated metastatic or unresectable colorectal adenocarcinoma received capecitabine 1000 mg/m2 twice daily on days 2-15 and intravenous irinotecan 100 mg/m2 on days 1 and 8, every 21 days. A total of 268 cycles of chemotherapy (median 6: range 1-11) were administered. According to an intent-to-treat analysis, the overall response rate was 49% (95% CI, 35-63%). Median time to progression and overall survival were 7.5 months (95% CI, 4.8-10.2) and 19.5 months (95% CI, 15.7-23.8), respectively. The most common grade 3/4 adverse events were diarrhea (24%) and neutropenia (11%). There were no treatment-related deaths. These results indicate that CAPIRI has comparable activity and tolerability to FOLFIRI as first-line treatment for advanced colorectal cancer.
Collapse
Affiliation(s)
- Tae Won Kim
- Section of Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
156
|
Kim JH, Jang HJ, Yoon HY, Lee SI, Kwon JH, Jung JY, Kim HJ, Song HH, Lee KS, Zang DY, Ahn JS, Park YI. Clinical Features of Hospitalized Adults with Infectious Mononucleosis. Korean J Hematol 2005. [DOI: 10.5045/kjh.2005.40.1.1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Jung Han Kim
- Department of Internal Medicine, Hallym University School of Medicine, Seoul, Korea
| | - Hyun Joo Jang
- Department of Internal Medicine, Hallym University School of Medicine, Seoul, Korea
| | - Hyeon Young Yoon
- Department of Internal Medicine, Hallym University School of Medicine, Seoul, Korea
| | - Soon Il Lee
- Department of Internal Medicine, Dankook University School of Medicine, Cheonan, Korea
| | - Jung Hye Kwon
- Department of Internal Medicine, Hallym University School of Medicine, Seoul, Korea
| | - Joo Young Jung
- Department of Internal Medicine, Hallym University School of Medicine, Seoul, Korea
| | - Hyo Jung Kim
- Department of Internal Medicine, Hallym University School of Medicine, Seoul, Korea
| | - Hun Ho Song
- Department of Internal Medicine, Hallym University School of Medicine, Seoul, Korea
| | - Keun Seok Lee
- Department of Internal Medicine, Hallym University School of Medicine, Seoul, Korea
| | - Dae Young Zang
- Department of Internal Medicine, Hallym University School of Medicine, Seoul, Korea
| | - Jin Seok Ahn
- Department of Internal Medicine, Hallym University School of Medicine, Seoul, Korea
| | - Young Iee Park
- Department of Internal Medicine, Hallym University School of Medicine, Seoul, Korea
| |
Collapse
|
157
|
Lee KS, Lee JA, Song HH, Byun J, Ahn JS, Zang DY, Park YI, Park SH, Park SW, Nam ES, Cho HC. Solitary dural extramedullary plasmacytoma with inv(9)(p13q21). Am J Clin Oncol 2004; 27:638-9. [PMID: 15577446 DOI: 10.1097/01.coc.0000147217.04752.00] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The authors report the case of a 24-year-old man who presented with a solitary dural extramedullary plasmacytoma (EMP) with inv(9)(p13q21). Chromosome 9 aberrations may be associated with the pathogenesis. This is the first reported case of solitary dural EMP associated with inv(9)(p13q21).
Collapse
Affiliation(s)
- Keun Seok Lee
- Department of Internal Medicine, Hallym University School of Medicine, Chunchon, Kangwon-do, Korea.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
158
|
Abstract
Chronic Neutrophilic Leukemia (CNL) is a rare myeloproliferative disorder characterized by a persistent increase of mature peripheral neutrophils, myeloid hyperplasia in bone marrow, hepatosplenomegaly, elevated neutrophil alkaline phosphatase (NAP) and absence of Philadelphia chromosome, with no evidence of infection or malignancy sufficient to mimic a leukemoid reaction. CNL has been associated with multiple myelomas in many reported cases, but transition of Polycythemia Vera (PV) to CNL is very rare. An 81-year-old female patient, who had undergone intermittent phlebotomy following the diagnosis of PV 8 years previously, was admitted to our hospital due to lower back pain. A physical examination showed a splenomegaly 2 cm below the costal margin, with tenderness of the thoracic and lumbar spine area. A peripheral blood examination showed a WBC count of 91,800/microL (neutrophil 88%) with a rare immature form, hemoglobin of 9.1 g/dL and a platelet count of 1,661,000/microL. Her NAP score was 58. The bone marrow examination showed 95% cellularity, with an M:E ratio of 10:1, increased megakaryocytes with normal morphology and the absence of myelofibrosis. Chromosomal studies showed no Philadelphia chromosome. A radiological examination showed compression fractures of the vertebrae and spinal cord compression. No underlying disease causing a leukemoid reaction was detected. With iron replacement, the hemoglobin level failed to increase over 12 g/dL. Therefore, it was concluded to be a transition of PV to CNL. After administration of hydroxyurea and vertebroplasty, the symptom improved and the WBC count was sustained below 40,000/microL.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Hyo Jung Kim
- Correspondence to : Hyo Jung Kim, M.D., Department of Internal Medicine, Hallym University Sacred Heart Hospital, 896 Pyungchon-dong, Dongan-gu, Anyang, Kyungki-do 431-070, Korea, TEL : 82-31-380-3859, FAX : 82-31-386-2269, E-mail :
| |
Collapse
|
159
|
Lee JA, Lee KS, Ahn JS, Byun JH, Song HH, Zang DY, Park YI, Park YS, Mo EK, Kim DK, Lee MG, Hyun IG, Jung KS, Bang SM, Park GY, Park JW, Cho EK, Jeong SH, Shin DB, Lee JH. A Phase II Study of Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Non-small-cell Lung Cancer. Cancer Res Treat 2003; 35:239-44. [PMID: 26680942 DOI: 10.4143/crt.2003.35.3.239] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
PURPOSE Paclitaxel and cisplatin, active drugs in the treatment of non-small-cell lung cancer (NSCLC), have been found to be synergistic and less myelotoxic in combination when the paclitaxel is given 24 hr prior to the cisplatin. Their antitumor activity and toxicity in patients with advanced NSCLC has been evaluated herein. MATERIALS AND METHODS Seventy-four chemonaive patients, with advanced NSCLC, were enrolled. Paclitaxel, 175 mg/m2, was administered on day 1, followed 24 hr later by cisplatin, 75 mg/m2, on day 2. RESULTS The overall response rate, median time to progression and median survival time were 51%, 7.1 months (95% confidence interval (CI), 5.5~8.7 months) and 13.7 months (95% CI, 11.3~16.1 months), respectively. There were significant differences in the overall survival rates in relation to stage and the ECOG performance status(PS). The toxicity was mainly nonhematological. Grade > or =3 neuropathy occurred in 2 (3%) patients, myalgia in 3 (4%), and bone pain in 3 (4%). The hematological toxicity was mild, and no grade 3 or 4 neutropenia was observed. CONCLUSION The combination of paclitaxel and cisplatin is an effective and tolerable treatment regimen for advanced NSCLC during first line chemotherapy. The main toxicity was nonhematological, such as peripheral neuropathy, myalgia and bone pain, whereas the hematological toxicity itself was mild.
Collapse
|
160
|
Lee HS, Zang DY, Seo YI, Kim DG, Kim EJ, Ahn JS, Park HR. A Small Cell Lung Cancer Concurrently Diagnosed with Paraneoplastic Dermatomyositis. Cancer Res Treat 2003; 35:161-4. [PMID: 26680931 DOI: 10.4143/crt.2003.35.2.161] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Dermatomyositis is an inflammatory myopathy, of unknown etiology, which is characterized by cutaneous rashes, accompanied by progressive and symmetric proximal muscle weakness. Especially in older people, the incidences of malignant conditions appear to be increased in dermatomyositis patients, and the prognosis is very poor. Because dermatomyositis may occur as a paraneoplastic syndrome, extensive screening tests, for an occult malignant neoplasm, should be conducted in older dermatomyositis patients. We experienced a case of small cell lung cancer, which had a very rapid and catastrophic clinical course, in a 63-year-old male patient with dermatomyositis. We report this case, and review the literature on the relationship of dermatomyositis and malignancy.
Collapse
|
161
|
Abstract
Involvement of the lower urinary tract by advanced non-Hodgkin's lymphoma (NHL) has been reported in up to 13% of cases, but primary NHL of the urinary bladder is very rare. A 35-year-old man was admitted to our hospital with a chief complaint of gross hematuria with left flank pain on April 12, 2001. Cystoscopy revealed an edematous broad-based mass on the left lateral wall of the bladder, and transurethral biopsy showed NHL, diffuse large B-cell type. Abdomino-pelvic CT scan demonstrated left-side hydronephrosis and hydroureter with left proximal ureter infiltration and thickening of the left lateral wall of the bladder with perivesical fat infiltration without lymph node enlargement. Full-scale staging work-up revealed the bone marrow as the solely involved site. The lesions of the bladder and left urinary tract were nearly completely regressed after two cycles of systemic cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy with simultaneous restoration of urinary function.
Collapse
Affiliation(s)
| | - Dae Young Zang
- Correspondence to: Dae Young Zang, M.D., Ph.D., Department of Internal Medicine, Hallym University Sacred Heart Hospital, 896 Pyungchon-dong, Dongan-gu, Anyang, Kyungki-do 431-070, Korea. E-mail:
| |
Collapse
|
162
|
Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001; 98:3058-65. [PMID: 11698291 DOI: 10.1182/blood.v98.10.3058] [Citation(s) in RCA: 100] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor necrosis factor (TNF) family, binds to several cell-surface receptors with distinct functions (agonistic receptors 1 and 2 [TRAIL-R1, TRAIL-R2]; decoy receptors 3 and 4 [TRAIL-R3, TRAIL-R4]). Expression and function was characterized in patients with myelodysplastic syndromes (MDSs). While normal marrow showed negligible expression of TRAIL and receptors (except TRAIL-R3), TRAIL and all receptors were constitutively expressed in MDS marrow. Following TRAIL exposure, MDS marrow showed significant increases in apoptosis, whereas normal marrow, except for a subset of CD34+ precursors, did not (P =.012). Marrow from 21 patients with MDS was then propagated in long-term cultures in the presence or absence of TRAIL. While in advanced MDS (refractory anemia with excess blasts in transformation [RAEB-T] and tAML [MDS transformed into AML]), colony numbers decreased in the presence of TRAIL (63.0% +/- 10.4% of untreated group [100%]), numbers increased in patients with RA or RAEB (160.2% +/- 90.5% of untreated group). TRAIL eliminated preferentially clonally abnormal cells as identified by chromosomal markers. Thus, TRAIL and receptor expression differed significantly between normal and MDS marrow, and TRAIL modulated in vitro hemopoiesis in MDS dependent upon disease stage but not, to a detectable extent, in normal marrow.
Collapse
Affiliation(s)
- D Y Zang
- Clinical Research Division, Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle, WA 98109-1024, USA
| | | | | | | | | |
Collapse
|
163
|
Zang DY, Deeg HJ, Gooley T, Anderson JE, Anasetti C, Sanders J, Myerson D, Storb R, Appelbaum F. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol 2000; 110:217-22. [PMID: 10931002 DOI: 10.1046/j.1365-2141.2000.02133.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We evaluated the outcome of allogeneic bone marrow transplantation (BMT) in 21 patients with chronic myelomonocytic leukaemia (CMML) who were treated at the Fred Hutchinson Cancer Research Center between 1990 and 1998. There were 11 male and 10 female patients with a median age of 47.4 years (range 1.0-62.9). Patients were conditioned either with total body irradiation (TBI) and chemotherapy, with or without antithymocyte globulin (n = 19), or with chemotherapy alone (n = 2). The marrow donor was an HLA-identical sibling in 12 patients, an HLA-non-identical related donor in three patients and an unrelated volunteer donor in six patients. All evaluable patients achieved sustained engraftment. Fifteen patients developed grades II-IV acute graft-versus-host disease (GVHD). Nine patients (43.0%) are surviving disease free at 0.7-8.1 years (median 6.9) after transplantation. Five patients relapsed 75-660 d after transplant and all died. Five patients died with organ failure and two died with GVHD and associated infections. The Kaplan-Meier estimates of disease-free survival and relapse at 3 years were 39% and 25% respectively. The probability of survival was improved in patients with shorter disease duration compared with those with a long interval from diagnosis to BMT. Thus, as with other myeloproliferative diseases or myelodysplastic syndromes, BMT offers curative therapy for a proportion of patients with CMML. We suggest that patients with CMML who have a suitable donor should be considered for transplantation, probably early in their disease course. However, it will be important to develop new regimens with enhanced antileukaemic efficacy without further increasing regimen-related toxicity and mortality.
Collapse
MESH Headings
- Adolescent
- Adult
- Antilymphocyte Serum/therapeutic use
- Bone Marrow Transplantation
- Child
- Child, Preschool
- Disease-Free Survival
- Female
- Graft vs Host Disease
- Humans
- Infant
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/radiotherapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/surgery
- Male
- Middle Aged
- Probability
- Proportional Hazards Models
- Recurrence
- Time Factors
- Transplantation Conditioning/methods
- Transplantation, Homologous
- Treatment Outcome
- Whole-Body Irradiation
Collapse
Affiliation(s)
- D Y Zang
- Clinical Research Division, Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Departments of Medicine, Paediatrics and Pathology, Seattle, WA 98109-1024, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
164
|
Zang DY, Lee KH, Lee JS, Lee JH, Kim WK, Kim SH, Kim WD, Kim DS, Kim JH, Kim BS, Cho YB, Kim DK, Kim KH. Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer. Am J Clin Oncol 1999; 22:495-8. [PMID: 10521066 DOI: 10.1097/00000421-199910000-00015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
A phase II trial of a novel platinum analog, SKI 2053R, was performed in patients with previously untreated extensive-stage disease (ED) small-cell lung cancer (SCLC). SKI 2053R was administered at the dose of 400 mg/m2 every 3 to 4 weeks as a 1-h infusion. After the first cycle, the dose was escalated to 440 mg/m2 based on toxicity. Thirty-eight patients (31 male) were enrolled between June 1995 and August 1997. The median age was 61 years (range, 36-70 years). Six of 37 evaluable patients achieved a partial response (16.2%; 95% confidence interval [CI], 4.4-28.0%). The durations of response were 1.1, 1.5, 1.7, 1.9, 3.4, and 4.6 months. The estimated median survival time was 7.4 months (95% CI, 5.1-9.7 months). Grade 3 or 4 toxicities were not observed. Grade 1 to 2 leukopenia, anemia, and thrombocytopenia were seen in 5 of 68 cycles, 16 of 68, and 2 of 68, respectively. Nonhematologic toxicities included grade 1 to 2 nausea or vomiting (30 of 68 cycles), nephrotoxicity (27 of 68), and hepatotoxicity (13 of 68). SKI 2053R showed a modest antitumor activity with limited toxicities in patients with ED SCLC. Further clinical trials are warranted in SCLC with a higher dose of SKI 2053R.
Collapse
Affiliation(s)
- D Y Zang
- Department of Medicine, University of Ulsan, and College of Medicine, Asan Medical Center, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
165
|
Choi JS, Lee KH, Ahn MJ, Lee JS, Lee JH, Zang DY, Suh CW, Kim SW, Kim WG, Kim JC, Kim SK, Park KC, Lee MS, Kim SH. A randomized trial comparing cisplatin plus 5-fluorouracil with or without levamisole in operable gastric cancer. Korean J Intern Med 1997; 12:155-62. [PMID: 9439150 PMCID: PMC4531987 DOI: 10.3904/kjim.1997.12.2.155] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
OBJECTIVES To determine the effectiveness and toxicity when levamisole was added to the adjuvant combination chemotherapy in patients with operable gastric cancer. METHODS After en bloc resection of gastric cancer without gross or microscopic evidence of residual disease from April 1991 to December 1992, 100 patients were randomized to 6 months of 5-fluorouracil 1,000 mg/m2/day administered as continuous infusion for 5 days, cisplatin 60 mg/m2/day as intravenous infusion for 1 day with or without levamisole (50 mg every eight hours P.O for a period of three days every 2 weeks for 6 months). This chemotherapy treatment was begun within 2 to 4 weeks after the surgery. The chemotherapy consisted of discrete 5-day courses administered at 4-weeks intervals. All 100 patients are assessable. RESULTS The fifty patients were assigned to each treatment group. There was no statistical difference and no bias in the distribution of characteristics of the 100 evaluable patients between the two groups. A total of 274 courses of treatment were given in the levamisole group and 260 courses of treatment in non-levamisole group. Eleven patients in each group did not finish planned 6 courses of treatment mainly due to non-compliance. At median follow up of 39 months, 32 patients relapsed 19 in the levamisole group and 13 in the non-levamisole group (p = 0.284). Twenty five patients died of relapsed diseases, 15 in the levamisole group and 10 in the non-levamisole group. The levamisole group tended to show more risk of overall death rate and recurrence than the non-levamisole group. However, this result was not statistically significant at 3 years. The treatment was well tolerated in both treatment groups. The grade 2-3 toxicities were nausea/ vomiting (levamisole, non-levamisole group; 31.7%, 29.3% of treatment courses respectively), diarrhea (7.6%, 8.4%), mucositis (11.6%, 12.3%), and leukopenia (9.8%, 9.6%). CONCLUSION Levamisole had negative effects on disease-free survival and overall survival when added to adjuvant combination chemotherapy of cisplatin and 5-fluorouracil in patients with operable gastric cancer. Both treatment arms were generally well tolerated and the toxicity profile was similar with or without levamisole.
Collapse
Affiliation(s)
- J S Choi
- Section of Hematology-Oncology, College of Medicine, University of Ulsan, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
166
|
Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997; 11:450-9. [PMID: 9092797 DOI: 10.1210/mend.11.4.9906] [Citation(s) in RCA: 223] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
An androgen receptor (AR) gene mutation identified in the androgen-dependent human prostate cancer xenograft, CWR22, changed codon 874 in the ligand-binding domain (exon H) from CAT for histidine to TAT for tyrosine and abolished a restriction site for the endonuclease SfaNI. SfaNI digestion of AR exon H DNA from normal but not from prostate cancer tissue indicated H874Y is a somatic mutation that occurred before the initial tumor transplant. CWR22, an epithelial cell tumor, expresses a 9.6-kb AR mRNA similar in size to the AR mRNA in human benign prostatic hyperplasia. AR protein is present in cell nuclei by immunostaining as in other androgen-responsive tissues. Transcriptional activity of recombinant H874Y transiently expressed in CV1 cells in the presence of testosterone or dihydrotestosterone was similar to that of wild type AR. With dihydrotestosterone at a near physiological concentration (0.01 nM), H874Y and wild type AR induced 2-fold greater luciferase activity than did the LNCaP mutant AR T877A. The adrenal androgen, dehydroepiandrosterone (10 and 100 nM) with H874Y stimulated a 3- to 8-fold greater response than with wild type AR and at 100 nM the response was similar with the LNCaP mutant. H874Y, like the LNCaP cell mutant, was more responsive to estradiol and progesterone than was wild type AR. The antiandrogen hydroxyflutamide (10 nM) had greater agonist activity (4- to 7-fold) with both mutant ARs than with wild type AR. AR mutations that alter ligand specificity may influence tumor progression subsequent to androgen withdrawal by making the AR more responsive to adrenal androgens or antiandrogens.
Collapse
Affiliation(s)
- J Tan
- Department of Pediatrics, School of Medicine, The University of North Carolina, Chapel Hill 27599, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
167
|
Lee KH, Lee JS, Suh CW, Kim SW, Kim SB, Lee JH, Zang DY, Lee DS, Chi HS, Lee MS, Kim WK, Kim SH. Prognostic factors of acute myelocytic leukemia: an analysis of 132 patients in a single institution. J Korean Med Sci 1996; 11:222-32. [PMID: 8843004 PMCID: PMC3054050 DOI: 10.3346/jkms.1996.11.3.222] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Patients with acute myelocytic leukemia (AML) have varied outlooks for survival after the diagnosis. To identify pretreatment prognostic indicators in AML, we analyzed 132 cases of AML seen at our hospital between June, 1989 and December, 1994. The median age of the patients was 40 years (range, 15-81). There were 63 male and 69 female patients. One hundred eight patients (82%) received induction chemotherapy which was based on cytarabine plus anthracyclines. Sixty six patients achieved complete remission (CR) and the CR rate among the patients given induction chemotherapy was 61%. The median duration of CR was 11.2 months. After median follow up of 6.6 months (range 0.5-51.4), 26 patients (39%) remain in continuous CR. The median duration of overall survival of the patients was 6.7 months. After median follow up of 10.6 months (range, 0.1-52.7), 41 patients (31%) are alive. Variables affecting duration of CR included the age of the patients, performance status of the patients, percentage of blast in the peripheral blood, hemoglobin level, percentage of blast in the bone marrow, FAB subtype, and CD7 marker positivity. Variables affecting survival duration included age of the patients, performance status of the patients, absolute blast count (ABC) in the peripheral blood, bone marrow cellularity, the percentage of blast in the bone marrow, and CD5 marker positivity. Multivariate analysis showed that the age of the patients and percentage of blast in the bone marrow were significant independent indicators for overall survival of the patients. Further studies utilizing cytogenetics and molecular characteristics of leukemic cell are warranted to better define the prognostic factors of patients with AML.
Collapse
Affiliation(s)
- K H Lee
- Department of Medicine, College of Medicine, University of Ulsan, Asan Medical Center, Spongpa-ku, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
168
|
Lee JH, Lee KH, Choi JS, Zang DY, Kim SB, Kim SW, Suh C, Lee JS, Kim WK, Lee YS, Kim SH. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment. J Korean Med Sci 1996; 11:118-26. [PMID: 8835758 PMCID: PMC3053940 DOI: 10.3346/jkms.1996.11.2.118] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Veno-occlusive disease (VOD) of the liver is a clinical syndrome characterized by hyperbilirubinemia, painful hepatomegaly, and fluid retention. In the bone marrow transplantation (BMT) setting, VOD is caused by dose-intensive chemotherapy and/or radiotherapy used to prepare patients for transplant. VOD occurs in up to 50% of the patients who undergo BMT and is usually associated with a high mortality rate. Until recently, there was no proven effective medical therapy for this condition once it was clinically apparent. We report here on the frequency and treatment result of VOD with rt-PA in our allogeneic BMT patients. Eight patients (median age 28.5 years) underwent allogeneic BMT from December, 1993 to June, 1995 in Asan Medical Center. Six leukemia patients were prepared for BMT with busulfan and cyclophosphmide, while two aplastic anemia patients received cyclophosphamide and antithymocyte globulin. VOD was defined as having two of the following features before day 20 posttransplant: jaundice (bilirubin > or = 2 mg/dL), tender hepatomegaly and/or right upper quadrant pain, ascites and/or unexplained weight gain (> 2% from baseline). All patients who were diagnosed with VOD received rt-PA (10-20 mg/day) and heparin (10,000 U/day). Three (37.5%) of the eight patients developed VOD that occurred between 6 and 10 days posttransplant. All three patients developed jaundice, weight gain, and tender hepatomegaly. Ascites and renal insufficiency occurred in two patients and pleural effusion in one patient. rt-PA and heparin were begun 6 to 26 days posttransplant and rt-PA was administered for 7 to 14 days. All three patients responded to the therapy; bilirubin levels began to decrease at 4 to 13 days from the start of therapy. They are all alive at day 111, 316, and 548 days posttransplant. None of the patients had significant hemorrhagic complications after rt-PA treatment. Prolonged administration of rt-PA was feasible without bleeding episode and it seems that rt-PA may alter the natural course of VOD.
Collapse
Affiliation(s)
- J H Lee
- Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
169
|
Tsai CS, Zang DY, Le P. High-packing-density multichannel integrated-optic modules in LiNbO(3) for a programmable correlation of binary sequences. Opt Lett 1989; 14:889-891. [PMID: 19753002 DOI: 10.1364/ol.14.000889] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Two 10-channel integrated-optic device modules have been constructed and tested. The architecture common to both modules consists of a LiNbO(3) composite waveguide 1.0 cm x 2.0 cm in size in which a channel-waveguide array, a planar waveguide, a linear microlens array, an electro-optic Bragg modulator array or an acousto-optic and electro-optic Bragg modulator array, and a large-aperture lens are integrated. A novel scheme that employs a linear ionmilled planar microlens array was devised to excite the entire channel-waveguide array simultaneously, and thus greatly facilitate testing and application of the two device modules. The performance characteristics obtained in programmable correlation of binary sequences are also presented.
Collapse
|
170
|
Le P, Zang DY, Tsai CS. Integrated electrooptic Bragg modulator modules for matrix-vector and matrix-matrix multiplications. Appl Opt 1988; 27:1780-1785. [PMID: 20531652 DOI: 10.1364/ao.27.001780] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Successful fabrication of high performance microlenses and microlens arrays using the titanium-indiffusion and proton-exchange technique has enabled realization of a variety of integrated electrooptic Bragg modulator modules in the LiNbO(3) channel-planar composite waveguides of 0.2- x 1.0- x 1.8-cm(3) substrate size. These integrated optic device modules have been utilized successfully to perform matrix-vector and matrix-matrix multiplications. Through the channel-waveguide and the linear microlens arrays, the very large channel capacities that are inherent in the diode laser and the optical fiber as well as the photodotcctor arrays may be conveniently exploited. Consequently, such integrated optic device modules should facilitate realization of multichannel optical computing as well as communication and rf signal processing systems.
Collapse
|
171
|
Zang DY, Tsai CS. Titanium-indiffused proton-exchanged waveguide lenses in LiNbO3 for optical information processing. Appl Opt 1986; 25:2264. [PMID: 18231487 DOI: 10.1364/ao.25.002264] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
|